No Data
No Data
Baird Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $46
Dyne Therapeutics Initiated With an Outperform at Baird
Insider Sale: Chief Scientific Officer of $DYN (DYN) Sells 2,334 Shares
Dyne Therapeutics(DYN.US) Director Sells US$3.99 Million in Common Stock
Dyne Therapeutics(DYN.US) Director Sells US$4.08 Million in Common Stock
Dyne Therapeutics(DYN.US) Director Sells US$3.27 Million in Common Stock